HIF-PHIs for Anemia Management in CKD Potential and Uncertainty ASCEND

Article Urology & Nephrology

被撤回的出版物: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis (Retracted article. See vol. 7, pg. 665, 2022)

Robert Provenzano et al.

Summary: The study showed that roxadustat was at least as effective as epoetin alfa in patients new to dialysis, with a lower risk of major adverse cardiovascular events and MACE+ in the roxadustat group compared to the epoetin alfa group.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Medicine, General & Internal

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis

Ajay K. Singh et al.

Summary: Among patients with CKD undergoing dialysis, daprodustat was found to be noninferior to ESAs in terms of change in hemoglobin levels and cardiovascular outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Ajay K. Singh et al.

Summary: This study compared the efficacy and safety of daprodustat and darbepoetin alfa in treating anemia in CKD patients not undergoing dialysis. The change in hemoglobin levels and cardiovascular outcomes were similar between the two groups during the study period.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

Steven Fishbane et al.

Summary: Roxadustat effectively increased hemoglobin levels and reduced the risk of red blood cell transfusion in non-dialysis-dependent CKD patients, with an adverse event profile similar to that of placebo.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Transplantation

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis

Robert Provenzano et al.

Summary: This study demonstrated the efficacy and safety of roxadustat in treating chronic kidney disease-related anemia. Roxadustat was shown to be as effective as epoetin alfa in correcting and maintaining hemoglobin levels, with comparable rates of adverse events.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD

Glenn M. Chertow et al.

Summary: Vadadustat, compared to darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not for cardiovascular safety in patients with NDD-CKD.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis

Kai-Uwe Eckardt et al.

Summary: Vadadustat, an oral prolyl hydroxylase inhibitor, was found to be noninferior to darbepoetin alfa in terms of cardiovascular safety and hemoglobin concentration in anemia patients with CKD undergoing dialysis, based on two phase 3 trials.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD Pooled Results of Three Randomized Clinical Trials

Robert Provenzano et al.

Summary: Roxadustat demonstrated superior efficacy in increasing hemoglobin levels compared to placebo, while also reducing the need for red blood cell transfusions. Furthermore, Roxadustat showed non-inferiority to placebo in terms of cardiovascular safety, including major adverse cardiovascular events.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

HIF-PHIs for Anemia Management in CKD Potential and Uncertainty ASCEND

相关参考文献

导出引文

分享论文